Since implanted biomaterials were born, there have been a series of problems, such as thrombogenesis, adhesion of bacteria, biocompatibility. All devices contacting blood should be nonthrombogenic, and how to improve the hemocompatibility of biomaterials is always maim task. However Biomaterials - Centered Infection (BCI) is increasing during these yars. In U. S. A. 850,000 BCIs were happening per year, which were occupied 45percent of all implanted cases. So BCI has become a big trouble which has restrained clinical application of biomaterials, especially implanted biomaterials.
展开▼
